drug

Radiolabeled PET tracer [18F]-DOPA

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
OTHER
Pre-approval / investigational in the US
Developed by Hoffmann-La Roche
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
OTHER

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia
NCT06880328Phase 1Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Hoffmann-La Roche
company
trial
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia
PHASE1
trial
indication
Schizophrenia
indication
Schizophrenia
indication